Alectinib, the current first-line standard of care for metastatic ALK+ lung cancers, yields objective tumor responses (<30% tumor shrinkage by RECIST) in ~50–75% of TKI-treated patients and progression free survival (PFS) ranges from ~10 to 30 months. The gene discussed is ALK; the disease is lung carcinoma.